^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral entry inhibitor

    Related drugs:
    10d
    ARN-75039 Lassa Fever Treatment in West Africa (clinicaltrials.gov)
    P2, N=135, Active, not recruiting, Arisan Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    14d
    VISTA: HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, TaiMed Biologics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    15d
    START-POAF: Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial (clinicaltrials.gov)
    P3, N=400, Recruiting, Population Health Research Institute | Trial completion date: Sep 2026 --> Nov 2028 | Trial primary completion date: Jun 2026 --> Aug 2028
    Trial completion date • Trial primary completion date
    20d
    Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, OHSU Knight Cancer Institute | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    22d
    Lipid‑disrupting effects of an organochlorine mixture in Sertoli TM4 cells reveal testicular obesogen mechanisms. (PubMed, Arch Toxicol)
    These responses differed from those elicited by a fatty acid mixture or the lipotoxicant amiodarone and did not appear to involve androgen receptor, aryl hydrocarbon receptor, or peroxisome proliferator‑activated α signaling, suggesting distinct lipid‑centered mechanisms...Notably, OC‑MIX selectively altered phospholipid and lysophospholipid species in Sertoli TM4 cells, indicating interference with membrane remodeling and lipid‑dependent signaling. Overall, these findings support the hypothesis that persistent organochlorines act as testicular obesogens, contributing to male reproductive dysfunction through selective, lipid‑disrupting mechanisms.
    Journal
    |
    AR (Androgen receptor)
    23d
    Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery (clinicaltrials.gov)
    P3, N=184, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    24d
    Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study (clinicaltrials.gov)
    P3, N=274, Recruiting, Ansun Biopharma, Inc. | Trial completion date: Aug 2025 --> Sep 2028 | Trial primary completion date: Aug 2025 --> Sep 2028
    Trial completion date • Trial primary completion date
    24d
    The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER) (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, CytoDyn, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Vyrologix (leronlimab)
    27d
    A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study) (clinicaltrials.gov)
    P3, N=160, Recruiting, Huahui Health | Not yet recruiting --> Recruiting
    Enrollment open
    29d
    SALIENT-AD: Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease (clinicaltrials.gov)
    P2, N=20, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Vyrologix (leronlimab)
    1m
    ECLIPSE 2: A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (clinicaltrials.gov)
    P3, N=150, Recruiting, Vir Biotechnology, Inc.
    Trial initiation date
    1m
    SALIENT-AD: Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Weill Medical College of Cornell University
    New P2 trial
    |
    Vyrologix (leronlimab)